The Vitals

FDA Approves Vabomere, 11th Antibiotic Under GAIN Act

August 31, 2017
FDA this week approved Rempex Pharmaceuticals' new antiobiotic Vabomer, the 11th new antibacterial drug approved since the Generating Antibiotics Incentives Now Act (GAIN Act) was signed into law, according to an agency spokesperson. Vabomer was designated as a qualified disease product and received priority review. The antibiotic is approved to treat adults with complicated urinary tract infections and a certain type of kidney infection, pyelonephritis. The approval is welcome news and evidence that the GAIN Act has provided an incremental...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, news from FDA and much more.